Biochemical steriod hormone receptor assays are of proven value in the prediction of clinical endocrine reponse in advanced breast cancer. However, they are costly and time consuming and can only be performed in especially equipped laboratories. In addition, they do not provide information regarding tissue or tumor cell heterogeneity. A valid histological method would circumvent many of the difficulties inherent in biochemistry. The estrogen receptor immunocytochemical assay (ERICA) appears to be such a method. Employing specific, antiestrophilin monoclonal antibodies, ERICA shows significant correlations with biochemical ER values as well as with clinical endocrine response. Further correlations of this nature are needed to provide a large data base. Preliminary evidence suggests a degree of positive interaction between the steriod binding sites detected by earlier histochemical methods (putative type II sites) and the type I site measured by biochemistry and ERICA. These interactions appear to allow for better discrimination in selecting candidates for hormonal therapy as well as in predictions of the disease-free interval and time of survival. Exploration and confirmation of these findings will be undertaken. Identification of progesterone receptors in intact tissue sections will also proceed. The ultimate aim of this project remains the same: to devise and evaluate histological techniques for the detection of steriod hormone binding sites in breast cancer, capable of performance and interpretation in the average hospital pathology laboratory.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
2R01CA023623-07
Application #
3166191
Study Section
Biochemical Endocrinology Study Section (BCE)
Project Start
1978-04-01
Project End
1988-08-31
Budget Start
1985-09-01
Budget End
1986-08-31
Support Year
7
Fiscal Year
1985
Total Cost
Indirect Cost
Name
Suny Downstate Medical Center
Department
Type
Schools of Medicine
DUNS #
068552207
City
Brooklyn
State
NY
Country
United States
Zip Code
11203
Prins, G S; Sklarew, R J; Pertschuk, L P (1998) Image analysis of androgen receptor immunostaining in prostate cancer accurately predicts response to hormonal therapy. J Urol 159:641-9
Pertschuk, L P; Feldman, J G; Kim, Y D et al. (1996) Estrogen receptor immunocytochemistry in paraffin embedded tissues with ER1D5 predicts breast cancer endocrine response more accurately than H222Sp gamma in frozen sections or cytosol-based ligand-binding assays. Cancer 77:2514-9
Pertschuk, L P; Masood, S; Simone, J et al. (1996) Estrogen receptor immunocytochemistry in endometrial carcinoma: a prognostic marker for survival. Gynecol Oncol 63:28-33
Pertschuk, L P; Schaeffer, H; Feldman, J G et al. (1995) Immunostaining for prostate cancer androgen receptor in paraffin identifies a subset of men with a poor prognosis. Lab Invest 73:302-5
Pertschuk, L P; Kim, Y D; Axiotis, C A et al. (1994) Estrogen receptor immunocytochemistry: the promise and the perils. J Cell Biochem Suppl 19:134-7
Pertschuk, L P; Macchia, R J; Feldman, J G et al. (1994) Immunocytochemical assay for androgen receptors in prostate cancer: a prospective study of 63 cases with long-term follow-up. Ann Surg Oncol 1:495-503
Pertschuk, L P; Feldman, J G; Kim, D S et al. (1993) Steroid hormone receptor immunohistochemistry and amplification of c-myc protooncogene. Relationship to disease-free survival in breast cancer. Cancer 71:162-71
Sklarew, R J; Bodmer, S C; Pertschuk, L P (1991) Comparison of microscopic imaging strategies for evaluating immunocytochemical (PAP) steroid receptor heterogeneity. Cytometry 12:207-20
Pertschuk, L P; Kim, D S; Nayer, K et al. (1990) Immunocytochemical estrogen and progestin receptor assays in breast cancer with monoclonal antibodies. Histopathologic, demographic, and biochemical correlations and relationship to endocrine response and survival. Cancer 66:1663-70
Sklarew, R J; Bodmer, S C; Pertschuk, L P (1990) Quantitative imaging of immunocytochemical (PAP) estrogen receptor staining patterns in breast cancer sections. Cytometry 11:359-78

Showing the most recent 10 out of 19 publications